Epirubicin is a type of chemotherapy medicine. It's used to treat certain kinds of cancer. It works by stopping cancer cells from growing and dividing. It's often given through an IV line into a vein.
Every report comes from a Lived member, sent anonymously.
Have you tried Epirubicin for Breast Cancer?
Epirubicin, sold in the US as Ellence and as a generic, is a chemotherapy medicine from the anthracycline family, a group of cancer drugs that also includes doxorubicin. It is given through a vein and is used in combination with other chemotherapy drugs. In the US, epirubicin is approved as part of adjuvant treatment for breast cancer, meaning chemotherapy given after surgery to lower the chance that the cancer comes back. It is meant for people whose cancer had spread to the lymph nodes under the arm (the axillary nodes) but not to distant parts of the body. Its usual partners are fluorouracil and cyclophosphamide, in combinations known by their initials as FEC or CEF. The approval rests on two large trials in women with node-positive breast cancer. In one, about 62 of every 100 people given an epirubicin combination were free of relapse five years later, compared with 53 of 100 given an older combination without an anthracycline (CMF). In the other, a higher epirubicin dose kept 65 of 100 relapse-free at five years, compared with 52 of 100 on half that dose. More people were alive at five years in the epirubicin and higher-dose groups as well. Outside its US approval, epirubicin has been used in combinations for stomach and esophageal cancers. In a large trial in people whose stomach cancer could be removed by surgery, a docetaxel-based combination called FLOT helped people live longer than an epirubicin-based one, so an oncologist may recommend a different regimen for these cancers.
Cells must copy their DNA before they divide. Epirubicin slips between the strands of DNA and interferes with topoisomerase II, an enzyme that cuts and rejoins DNA so it can be untangled during copying. The result is broken DNA and blocked production of RNA and proteins, and the cell dies. The drug also generates reactive molecules called free radicals that add to the damage. Researchers do not fully understand which of these effects matters most. Because this damage falls hardest on cells that divide often, cancer cells are the main target, but fast-growing healthy cells are affected too. That is why blood counts drop, hair falls out and the lining of the mouth becomes sore. These tissues usually recover between cycles. The heart is affected differently: anthracyclines can injure heart muscle, and that injury can be permanent, which is why the total amount a person receives over a lifetime is limited.
Epirubicin is given in a hospital or infusion center by staff trained to handle chemotherapy. The red liquid is run into the tubing of an IV drip that is already flowing, usually over about 15 to 20 minutes, rather than pushed straight into the vein. Treatment is given in cycles every three or four weeks. Depending on the regimen, the full dose is given on the first day of a cycle or split between day 1 and day 8. In the breast cancer regimens studied for approval, people received six cycles. The dose is calculated from height and weight (body surface area) and adjusted according to how the previous cycle went. It is lowered for people with liver problems and may be lowered for severe kidney problems, so liver and kidney blood tests come before and during treatment. Anti-nausea medicines are usually given before each dose. People on the higher-dose regimen also take preventive antibiotics because of the infection risk when white blood cell counts fall. Epirubicin can cause severe tissue damage, sometimes needing surgery and skin grafts, if it leaks out of the vein. Tell the nurse at once about any burning or stinging at the IV site during the infusion; a leak can also happen without pain, which is one reason staff watch the site closely. Pain at the injection site in the days afterward also needs a call to the care team.
Hair loss affects nearly everyone at the doses used for breast cancer, and hair usually grows back within two to three months after treatment ends. Nausea and vomiting are very common in the first days after a dose and are easier to control with medicines given in advance; severe vomiting should be reported because it can cause dehydration. Mouth sores tend to appear soon after a dose and usually heal by the third week. Tiredness, diarrhea, hot flashes, sore or irritated eyes, rash and itching are also common, and many people stop having periods during treatment. Urine can look red for a day or two after each dose. This is the drug's color and is harmless. The most important short-term risk is a drop in blood counts. White blood cells, which fight infection, usually reach their lowest point 10 to 14 days after a dose and recover by about day 21. A new fever or signs of infection, such as chills, during treatment need a call to the oncology team right away, because infections can become serious quickly while white cells are low. Low platelets and red blood cells can cause bleeding and fatigue and sometimes require transfusions. Epirubicin can damage the heart muscle, either during treatment or months to years later. New chest pain, shortness of breath, dizziness or lightheadedness call for contacting the care team immediately or going to an emergency room. Less often, epirubicin causes blood clots in the veins, including clots that travel to the lungs, allergic reactions, and inflammation flaring in skin or other tissue that was treated earlier with radiation (radiation recall). It also slightly raises the risk of a later leukemia or a related bone marrow disorder called myelodysplastic syndrome. In a large analysis of people treated for early breast cancer, about 0.55% (roughly 1 in 180) developed one within eight years, most often within one to three years of treatment.
Heart risk shapes much of how epirubicin is used. The chance of heart muscle damage rises with the total amount received over a lifetime, measured in milligrams per square meter of body surface (mg/m2). In the label's data, about 0.9% of people developed it after a lifetime total of 550 mg/m2, 1.6% after 700 and 3.3% after 900, and totals of 900 are generally avoided. Damage can still happen at lower totals. Before treatment, and regularly during and after it, the care team checks the left ventricular ejection fraction (LVEF), the share of blood the heart's main pumping chamber pushes out with each beat, using a heart scan. A meaningful drop can lead to stopping the drug. Existing heart disease, earlier treatment with another anthracycline such as doxorubicin, past radiation to the chest, and other medicines that strain the heart all add to the risk. Trastuzumab (Herceptin), a targeted treatment for HER2-positive breast cancer, is the main example: it can stay in the body for up to seven months, so epirubicin is avoided for that long after trastuzumab stops when possible, and the heart is watched closely if it cannot wait. Calcium channel blockers, a group of medicines used for blood pressure and some heart conditions, also call for closer heart monitoring. Epirubicin is not given to people with severely weakened heart muscle, a recent heart attack or serious heart rhythm problems, people who have already received the maximum lifetime dose of anthracyclines, people with severe liver disease, or people whose blood counts remain severely low from earlier treatment. Cimetidine, an acid-reducing medicine sold over the counter, raises epirubicin levels and should be stopped during treatment. Live vaccines should not be given during treatment; inactivated vaccines are allowed but may work less well. The oncology team should know about every medicine and supplement. Epirubicin can harm a developing baby, so a pregnancy test is done before starting. Women who could become pregnant should use effective contraception during treatment and for six months after the last dose. Men with partners who could become pregnant should use contraception for three months after the last dose, and condoms for at least seven days if a partner is already pregnant. Breastfeeding should stop during treatment and for at least seven days afterward. Epirubicin can also impair fertility: periods may stop permanently or menopause may come early, with recovery depending partly on age, and sperm production can fall, sometimes for good.
A course of epirubicin-based treatment for breast cancer usually runs about four to six months: six cycles of three or four weeks each. Each cycle tends to follow a pattern. Nausea and tiredness are worst in the first days, mouth sores may appear early, and blood counts are lowest around the second week before recovering. Blood counts are checked before every cycle, and the next dose may be delayed or reduced if they have not recovered or side effects were severe. Liver and kidney tests and heart checks continue through treatment. In the trials behind the breast cancer approval, radiation to the breast was given after chemotherapy was finished, partly because epirubicin can intensify radiation's effects on healthy tissue. Hair begins to grow back within a few months of the last dose, and most short-term effects fade as the bone marrow and mouth lining recover. Some effects outlast treatment. Heart problems can first appear months or years later, so heart follow-up continues after chemotherapy ends, and new breathlessness even years afterward is worth raising with a doctor. Periods may or may not return. The small risk of leukemia is highest in the first few years. Because the aim of adjuvant chemotherapy is to lower the chance of the cancer returning, its benefit is not something a person feels; it shows up over years of follow-up.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Epirubicin, what you've noticed, or ask the community a question.